Numerous rheumatoid arthritis (RA) disease activity measurement tools are currently
available for use. The psychometric data related to these tools have been published over the …

Background Improved understanding of rheumatoid arthritis (RA) pathogenesis has led to
the development of new biologic treatments that target specific elements of RA inflammatory …

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …

Background Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2
that may have therapeutic value in patients with rheumatoid arthritis. Methods We conducted …

Objective To report long-term safety from the completed extension trial of baricitinib, an oral
selective Janus kinase inhibitor, in patients with active rheumatoid arthritis (RA). Methods …

Importance Proactive therapeutic drug monitoring (TDM), defined as individualized drug
dosing based on scheduled monitoring of serum drug levels, has been proposed as an …

Background In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced
disease activity in patients with rheumatoid arthritis who had not previously received …

Importance Patients with active rheumatoid arthritis (RA) despite treatment with biologic
disease-modifying antirheumatic drug (bDMARD) therapy need treatment options. Objective …

Objective We undertook this phase III study to evaluate baricitinib, an orally administered
JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to …

Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor.
Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying …